Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Abstract Background Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients receiving erlotinib treatment prompting delay or termination of treatment. Only a few factors related to hepatotoxic...

Full description

Bibliographic Details
Main Authors: Min Kyoung Kim, Jeong Yee, Yoon Sook Cho, Hong Won Jang, Ji Min Han, Hye Sun Gwak
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Erlotinib
Hepatotoxicity
CYP3A4 inducers
H2-antagonist
Proton pump inhibitor
Online Access:http://link.springer.com/article/10.1186/s12885-018-4891-7

Internet

http://link.springer.com/article/10.1186/s12885-018-4891-7

Similar Items